[<sup>18</sup>F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer

Authors
Publication date
Publisher
'Springer Fachmedien Wiesbaden GmbH'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Newcastle University E-Prints

    redirect
    oaioai:eprints.ncl.ac.uk:288547
    Last time updated on 29/01/2023